Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
Authors' conclusion
The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allow the study to garner information about the CV benefits of semaglutide across these relevant clinical subgroups.
Study context
- Population
- Individuals with overweight or obesity without diabetes, with prior MI, stroke and/or peripheral artery disease72.5% male
- Participants
- 17,605 individuals
- Comparison
- Semaglutide vs placebo; baseline characteristics reported
Primary result
As reported in the abstract
Baseline characteristics
- Age, mean (SD)
- 61.6 (8.9) years
- BMI, mean (SD)
- 33.34 (5.04) kg/m²
- Prior MI
- 76.3%
- Prior stroke
- 23.3%
- Peripheral artery disease
- 8.6%
- HF diagnosis
- 24.3%
- HbA1c in prediabetes range (5.7%-6.4%)
- 66%
Further findings
Cardiovascular (CV) risk factors across HbA1c subgroups · baseline
- Across groups of increasing HbA1c, prevalence of all CV risk factors increased
Original publication
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring). Published 10 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →